Please wait...
| ID | PMID | YEAR | Sequence | Name | Length | N-ter MOD | C-ter MOD | Linear/Cyclic | Chirality | Chem-MOD | Origin | Nature | Incubation Time | Concentration | Half Life | Units Half Life | Protease | Assay | Test Sample | Vivo/Vitro | Reference | Patent No. | Activity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2147696 | 1990 | Synthetic peptide | 10 | Free | Free | Linear | L | None | Synthetic peptide (corresponding to amino acids 605-614 of human protein S) | Anticoagulant | Not reported | Not mentioned | 80 | Rabbit blood proteases | Spectrofluorometry | Intravenously injected in male New Zealand white rabbits and blood samples withdrawn and plasma sample prepared | in vivo | None | None | 34% of 125I protein S bound to C4b-binding protein in presence of 150 µM of peptide | |||
| 2147696 | 1990 | Control peptide | 8 | Free | Free | Linear | L | None | Synthetic peptide (scrambled amino acids of human protein S) | Anticoagulant | Not reported | Not mentioned | 15 | Rabbit blood proteases | Spectrofluorometry | Intravenously injected in male New Zealand white rabbits and blood samples withdrawn and plasma sample prepared | in vivo | None | None | No activity found | |||
| 2147696 | 1990 | Control peptide | 10 | Free | Free | Linear | L | None | Synthetic peptide (amino acids 400-407 of human protein S) | Anticoagulant | Not reported | Not mentioned | 15 | Rabbit blood proteases | Spectrofluorometry | Intravenously injected in Male New Zealand white rabbits and blood samples withdrawn and plasma sample prepared | in vivo | None | None | No activity found | |||
| 2533571 | 1989 | Des-enkephalin-γ-endorphin | 12 | Free | Free | Linear | L | None | Endorphin derivative | Neuropeptide | Not reported | 0.1mM | 4.5 | Proteases in SVK14 keratinocytes | HPLC/liquid scintillation counting | SVK14 keratinocytes | in vitro | 3582424 | None | Not reported | |||
| 2533571 | 1989 | Des-enkephalin-γ-endorphin | 12 | Free | Free | Linear | L | None | Endorphin derivative | Neuropeptide | Not reported | 0.1mM | 4.1 | Proteases in fibroblasts | HPLC/liquid scintillation counting | Human fibroblasts | in vitro | 3582424 | None | Not reported | |||
| 2533571 | 1989 | Des-enkephalin-γ-endorphin | 12 | Free | Free | Linear | L | None | Endorphin derivative | Neuropeptide | Not reported | 0.1mM | 4.4 | Proteases in human fresh whole skin | HPLC/liquid scintillation counting | Human fresh whole skin | in vitro | 3582424 | None | Not reported | |||
| 2533571 | 1989 | Des-enkephalin-γ-endorphin | 12 | Free | Free | Linear | L | None | Endorphin derivative | Neuropeptide | Not reported | 0.1mM | 4.6 | Proteases in human fresh epidermis | HPLC/liquid scintillation counting | Human fresh epidermis | in vitro | 3582424 | None | Not reported | |||
| 2533571 | 1989 | Des-enkephalin-γ-endorphin | 12 | Free | Free | Linear | L | None | Endorphin derivative | Neuropeptide | Not reported | 0.1mM | 4.5 | Proteases in human fresh dermis | HPLC/liquid scintillation counting | Human fresh dermis | in vitro | 3582424 | None | Not reported | |||
| 659633 | 1978 | C-peptide | 31 | Free | Free | Linear | L | None | Proinsulin | Not mentioned | Not reported | 0.75pmol/ml | 33.5(mean) | Not mentioned | Single-dose injection technique | 6 Normal human male blood plasma sample | in vivo | None | None | Not mentioned | |||
| 659633 | 1978 | C-peptide | 31 | Free | Free | Linear | L | None | Proinsulin | Not mentioned | Not reported | 0.9pmol/ml | 42.5(mean) | Not mentioned | Single-dose injection technique | 7 Diabetic human male blood plasma sample | in vivo | None | None | Not mentioned | |||
| 3080478 | 1985 | C0-LAP | 15 | Free | Free | Linear | L | None | Lipid associated peptide -20 | Not mentioned | Not reported | 300 µl | ~300 | Not mentioned | Serum decay experiment | Blood sample of female Sprague-Dawley rat | in vivo | 6774331 | None | Not mentioned | |||
| 3080478 | 1985 | C4-LAP | 15 | Saturated acyl chain of 4 carbons | Free | Linear | L | None | Lipid associated peptide -20 | Not mentioned | Not reported | 300 µl | ~340 | Not mentioned | Serum decay experiment | Blood sample of female Sprague-Dawley rat | in vivo | 6774331 | None | Not mentioned | |||
| 3080478 | 1985 | C8-LAP | 15 | Saturated acyl chain of 8 carbons | Free | Linear | L | None | Lipid associated peptide -20 | Not mentioned | Not reported | 300 µl | ~410 | Not mentioned | Serum decay experiment | Blood sample of female Sprague-Dawley rat | in vivo | 6774331 | None | Not mentioned | |||
| 3080478 | 1985 | C12-LAP | 15 | Saturated acyl chain of 12 carbons | Free | Linear | L | None | Lipid associated peptide -20 | Not mentioned | Not reported | 300 µl | ~410 | Not mentioned | Serum decay experiment | Blood sample of female Sprague-Dawley rat | in vivo | 6774331 | None | Not mentioned | |||
| 3080478 | 1985 | C16-LAP | 15 | Saturated acyl chain of 16 carbons | Free | Linear | L | None | Lipid associated peptide -20 | Not mentioned | Not reported | 300 µl | 513 ±12 | Not mentioned | Serum decay experiment | Blood sample of female Sprague-Dawley rat | in vivo | 6774331 | None | Not mentioned | |||
| 3343338 | 1987 | Anti-cell adhesive pentapeptide | 5 | Free | Free | Linear | L | None | Central cell- binding domain of fibronectin | Anti metastatic | Not reported | 6 µmol | 8 | Not mentioned | Radioactivity measured by scintillation counter | Blood sample of C57BL/6 mice | in vivo | None | None | Percentage inhibition of melanotic colony formation=90 | |||
| 6086405 | 1984 | Hydra head activator | 11 | Free | Free | Linear | L | Glp-Pyroglutamic acid | Hydra but also found in rat intestine,human and bovine hypothalamus | In hydra-stimulatory effects on growth and differentition,in human-in digestion control process | 2 hour | 20-100 fmol/ml | 7 | Not mentioned | Radioimmunoassay | Human plasma | in vitro | None | None | Not mentioned | |||
| 6117506 | 1981 | Somatostatin | 14 | Free | Free | Cyclic (C3-C14) | L | None | Ovine | Local transmitters either paracrine or neurocrine | 5 days | 100ng | 1.0 ±0.2 | Not mentioned | Radioimmunoassay | Blood plasma sample from five mongrel dogs | in vivo | 4682131 | None | Not mentioned | |||
| 7439398 | 1980 | Glutathione | 3 | Free | Free | Linear | L | Gamma peptide linkage between the carboxyl group of the glutamate side-chain and the amine group of cysteine | Synthetic | Not mentioned | Not reported | 25 ng/kg/min of Bradykinin and the rate doubled every 5 min until a final rate of 200 ng/kg/min was | 1.6 | Not mentioned | Kinetic assay | Human blood plasma sample | in vivo | None | None | Not mentioned | |||
| 3799211 | 1986 | (I-deamino-8-D-arginine vasopressin)DDAVP | 9 | 1-β-mercaptopropionic acid | Free | Linear | Mix | None | Modified form of Vasopressin | Antidiuretic agent | Not reported | 90mg | 200 | Plasma proteases | Radioimmunoassay | Blood sample of human uraemic patients(end stage renal failure) | in vivo | US 5500413 A patent | None | Not mentioned | |||
| 3799211 | 1986 | (I-deamino-8-D-arginine vasopressin)DDAVP | 9 | 1-β-mercaptopropionic acid | Free | Linear | Mix | None | Modified form of Vasopressin | Antidiuretic agent | Not reported | 45mg | 55 | Plasma proteases | Radioimmunoassay | Human blood sample | N.A. | None | US 5500413 A patent | Not mentioned | |||
| 1697165 | 1990 | Atrial natriuretic peptide (ANP) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Atrial natriuretic peptide | Natriuretic, diuretic and vasorelaxant | Not reported | 0.17-0.25 MBq | 0.42 ±0.03 | Rat blood proteases | Radioimmunoassay and RP-HPLC | Rat blood plasma (infused into fumoral vein and right carotid artery) | in vivo | None | None | Not given | |||
| 1697165 | 1990 | ANP' | 26 | Free | Free | Cyclic | L | None | Atrial natriuretic peptide | Natriuretic, diuretic and vasorelaxant | Not reported | 0.17-0.25 MBq | 1.04 | Rat blood proteases | Radioimmunoassay and RP-HPLC | Rat blood plasma (infused into fumoral vein and right carotid artery) | in vivo | None | None | Not given | |||
| 1697165 | 1990 | Atrial natriuretic peptide (ANP) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Atrial natriuretic peptide | Natriuretic, diuretic and vasorelaxant | Not reported | 0.17-0.25 MBq | 7.81 ± 0.38 | Kallikrein and Endopeptidase 24.11 in presence of inhibitor Phosphoramidon | Radioimmunoassay and RP-HPLC | Rat blood plasma (infused into fumoral vein and right carotid artery) | in vivo | None | None | Not given | |||
| 1697165 | 1990 | Atrial natriuretic peptide (ANP) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Atrial natriuretic peptide | Natriuretic, diuretic and vasorelaxant | Not reported | 0.17-0.25 MBq | 2.51 ±0.25 | Kallikrein and Endopeptidase 24.11 in presence of inhibitor Aprotinin | Radioimmunoassay and RP-HPLC | Rat blood plasma (infused into fumoral vein and right carotid artery) | in vivo | None | None | Not given | |||
| 1697165 | 1990 | Atrial natriuretic peptide (ANP) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Atrial natriuretic peptide | Natriuretic, diuretic and vasorelaxant | Not reported | 0.17-0.25 MBq | 15.2 ± 1.01 | Kallikrein and Endopeptidase 24.11 in presence of inhibitors phosphoramidon and aprotinin both | Radioimmunoassay and RP-HPLC | Rat blood plasma (infused into fumoral vein and right carotid artery) | in vivo | None | None | Not given | |||
| 3348603 | 1987 | DihydromycoplanecinA (DHMP A) | 10 | alpha-hydroxybutyric acid | Free | Cyclic | L | N-MeVal; N-methylvaline, EtPro; Ethylproline, N-MeThr; N-methylthreonine MePro; Methylproline, AMHA; 2-amino-5-methylhexanoic acid, N-MeLeu; N-methylleucine | Active metabolite in urine of mice and dogs | Antibiotic | Not reported | 10 mg/kg | 0.5 | Mouse blood proteases | Not mentioned | Mice serum (Intravenous) | in vivo | None | None | LD50>6000mg/kg administered orally to mice | |||
| 3348603 | 1987 | DihydromycoplanecinA (DHMP A) | 10 | alpha-hydroxybutyric acid | Free | Cyclic | L | N-MeVal; N-methylvaline, EtPro; Ethylproline, N-MeThr; N-methylthreonine MePro; Methylproline, AMHA; 2-amino-5-methylhexanoic acid, N-MeLeu; N-methylleucine | Active metabolite in urine of mice and dogs | Antibiotic | Not reported | 10 mg/kg | 19.3 | Mouse blood proteases | Not mentioned | Mice serum (Intravenous) | in vivo | None | None | LD50>6000mg/kg administered orally to mice | |||
| 3348603 | 1987 | DihydromycoplanecinA (DHMP A) | 10 | Free | Free | Cyclic | L | N-MeVal; N-methylvaline, EtPro; Ethylproline, N-MeThr; N-methylthreonine MePro; Methylproline, AMHA; 2-amino-5-methylhexanoic acid, N-MeLeu; N-methylleucine | Active metabolite in urine of mice and dogs | Antibiotic | Not reported | 10 mg/kg | 5.5 | Dog blood proteases | Not mentioned | Dog serum (Intravenous) | in vivo | None | None | LD50>6000mg/kg administered orally to mice | |||
| 6117506 | 1981 | Vasoactive Intestinal Peptide | 28 | Free | Amidation | Linear | L | None | Porcine vasoactive intestinal peptide | Vasoactive intestinal peptide | Not reported | 103.7 ± 14.8 ml/kg | 1.80 ± 0.1 | Dog blood proteases | Radioimmunoassay | Dog plasma (Intravenous) | in vivo | None | None | 150-220 µci/ µg | |||
| 385880 | 1979 | 5-Fluoro-4-(N-succinamoylglycylglycine benzyl ester)-2(1H)-pyrimidone (compound 11) | 2 | 5-Fluoro-4-N-succinamoyl | Benzyl ester-2(1H)-pyrimidone | Linear | L | Conjugation of peptide C terminal carboxyl group with amino group of 5 Fluorocytosine | Synthetic | Anticandidal | Not given | Not mentioned | 0.3 | Sample cells proteases | Spectrophotometry | Sample cells | in vivo | None | None | 5-FC peptide were tested for antifungal activity agaainst S. cerevisiae, Candida albicans and candida. The MIC was 0.62,0.62 and 20 µg/mL respectively. | |||
| 385880 | 1979 | 5-Fluoro-4-(N -succinamoyl-L-alanyl-L-leucine)-2-(1H)-pyrimidone (compound 12) | 2 | 5-Fluoro-4-N-succinamoyl | 2-(1H)-pyrimidone | Linear | L | Conjugation of peptide C terminal carboxyl group with amino group of 5 Fluorocytosine | Synthetic | Anticandidal | Not given | Not mentioned | 1.7 | Sample cells proteases | Spectrophotometry | Sample cells | in vivo | None | None | 5-FC peptide were tested for antifungal activity agaainst S. cerevisiae, Candida albicans and candida. The MIC was 0.31,0.31 and 10 µg/mL respectively. | |||
| 385880 | 1979 | 5-Fluoro-4-(N-succinamoyl-L-alanyl-L-leucine benzyl ester)-2(1H)-pyrimidone (compound 9) | 2 | 5-Fluoro-4-N-succinamoyl | Benzyl ester-2(1H)-pyrimidone | Linear | L | Conjugation of peptide C terminal carboxyl group with amino group of 5 Fluorocytosine | Synthetic | Anticandidal | Not given | Not mentioned | 1.1 | Sample cells proteases | Spectrophotometry | Sample cells | in vivo | None | None | 5-FC peptide were tested for antifungal activity agaainst S. cerevisiae, Candida albicans and candida. The MIC was 0.31,0.62 and 20 ug/mL respectively. | |||
| 385880 | 1979 | 5-Fluoro-4-(N -succinamoyl-L-leucyl-L-leucine)-2(1 H)-pyrimidone (compound13) | 2 | 5-Fluoro-4-N-succinamoyl | 2-(1H)-pyrimidone | Linear | L | Conjugation of peptide C terminal carboxyl group with amino group of 5 Fluorocytosine | Synthetic | Anticandidal | Not given | Not mentioned | 2.9 | Sample cells proteases | Spectrophotometry | Sample cells | in vivo | None | None | 5-FC peptide were tested for antifungal activity agaainst S. cerevisiae, Candida albicans and candida. The MIC was 0.31,0.31 and 10 µg/mL respectively. | |||
| 385880 | 1979 | N4-( Boc-Ala-Gly)-5-FC (compound 17) | 2 | N4- Boc | 5-FC (5 Fluorocytosine) | Linear | L | Conjugation of peptide C terminal carboxyl group with amino group of 5 Fluorocytosine | Synthetic | Anticandidal | Not given | Not mentioned | 2.3 | Sample cells proteases | Spectrophotometry | Sample cells | in vivo | None | None | 5-FC peptide were tested for antifungal activity agaainst S. cerevisiae, Candida albicans and candida. The MIC was 0.62, 0.62 and 1.25 ug/mL respectively. | |||
| 641324 | 1983 | Peptide histidine isoleucine | 27 | Free | Free | Linear | L | None | Porcine intestine | Neurotransmitter | 1, 2, 3, 4, 5, 10 and 15 min. | 4.7 pmoles/kg | 3.1 ±0.5 | Human plasma proteases | Radioimmunoassay | Intravenous administration to human plasma | in vivo | None | None | PHI effect on secretion on gastrointestinal hormone and monitor its effect on gastric secretion of pepsin. PHI infused at 4.7pmoles/kg in human and gastric juice were aspirated by suction, gastric secretion was improved to be in case of PIH. | |||
| 3922013 | 1984 | Calcitonin gene related peptide | 37 | Free | Free | Linear | L | None | Human non-thyroidal tissue | Vasoactive neuropeptide | Not given | 0.32 pmol/kg | 6.9 ±0.9 (first phase) | Human blood plasma proteases | Radioimmunoassay | Intravenous injection into human | in vivo | http://physrev.physiology.org/content/94/4/1099 | None | CGRP infusion reduces gastric acid output as measured by plasma concentration of CGRP against time data obtained during infusion. | |||
| 3922013 | 1984 | Calcitonin gene related peptide | 37 | Free | Free | Linear | L | None | Human non-thyroidal tissue | Vasoactive neuropeptide | Not given | 2.56 pmol/kg | 26.4 ±4.7 (first phase) | Human blood plasma proteases | Radioimmunoassay | Intravenous injection into human | in vivo | http://physrev.physiology.org/content/94/4/1099 | None | CGRP infusion reduces gastric acid output as measured by plasma concentration of CGRP against time data obtained during infusion. | |||
| 4034413 | 1985 | Leucine enkephalin | 5 | Free | Free | Linear | L | None | Human brain | Analgesic | 20 minutes | 0.9 nM | 14.7 | Human serum protease | HPLC | Human serum | in vitro | None | None | Not reported | |||
| 4034413 | 1985 | Leucine enkephalin analogue | 5 | Free | Free | Linear | L | Thiomethylene bond replacement between residue 1-2 | Derivative of Natural enkephalin | Analgesic | 20 minutes | 0.9 nM | 94 | Human serum protease | HPLC | Human serum | in vitro | None | None | Not reported | |||
| 4034413 | 1985 | Leucine enkephalin analogue | 5 | Free | Free | Linear | L | Thiomethylene bond replacement between residue 2-3 | Derivative of Natural enkephalin | Analgesic | 20 minutes | 0.9 nM | 79.4 | Human serum protease | HPLC | Human serum | in vitro | None | None | Not reported | |||
| 4034413 | 1985 | Leucine enkephalin analogue | 5 | Free | Free | Linear | L | Thiomethylene bond replacement between residue 4-5 | Derivative of Natural enkephalin | Analgesic | 20 minutes | 0.9 nM | 315 | Human serum protease | HPLC | Human serum | in vitro | None | None | Not reported | |||
| 4034413 | 1985 | Leucine enkephalin analogue | 5 | Free | Free | Linear | Mix | Thiomethylene bond replacement between residue 3-4 | Derivative of Natural enkephalin | Analgesic | 20 minutes | 0.9 nM | >1000 | Human serum protease | HPLC | Human serum | in vitro | None | None | Not reported | |||
| 4070016 | 1985 | DTγE( Des-Tyr1-γ-Endorphin) (β-endorphin-(2-17)) | 16 | Free | Free | Linear | L | None | CNS and piyuitary gland of Humans | Neuropeptide, non-opioid y-type endorphins | Not given | 3.1-7.1 µg | 0.7 (distribution phase) | Rat blood proteases | RP-HPLC | Male wistar Rats (intravenously) | in vivo | None | None | Not reported | |||
| 4070016 | 1985 | DTγE( Des-Tyr1-γ-Endorphin) (β-endorphin-(2-17)) | 16 | Free | Free | Linear | L | None | CNS and piyuitary gland of Humans | Neuropeptide, non-opioid y-type endorphins | Not given | 3.1-7.1 µg | 5.5 (elimination phase) | Rat blood proteases | RP-HPLC | Male wistar Rats (intravenously) | in vivo | None | None | Not reported | |||
| 4070016 | 1985 | DEγE (Des-Enkephalin-γ-Endorphin) (β-endorphin-(6--17)) | 12 | Free | Free | Linear | L | None | CNS and piyuitary gland of Humans | Neuropeptide, non-opioid y-type endorphins | Not given | 1.0-1.15 µg | 0.6 (distribution phase) | Rat blood proteases | RP-HPLC | Male wistar Rats (intravenously) | in vivo | None | None | Not reported | |||
| 6121002 | 1982 | PLG peptide | 3 | Free | Free | Linear | L | Tritium labeling at Proline | Hypothalamus and pineal gland | Interact with dopaminergic system and improve patients of parkinson disease | Not given | 2 - 2.5 μg | 20 (t1/2 elimination) | Rat plasma proteases | Radioimmunoassay | Subcutaneously injected to rat plasma | in vivo | None | None | Radiolabelled peptide was administered in rats and blood plasma was taken and analysed by HPLC. Brain level of radioactivity increased with time. | |||
| 6127205 | 1982 | Somatostatin 14 | 14 | Free | Free | Cyclic (C3-C14) | L | None | Ovine hypothalamus | Regulates the endocrine system and affects neurotransmission and cell proliferation | 30-45 minute | 10 µg | 1.7 ±0.2 | Dog blood proteases | SS Radioimmunoassay assay | Intravenous infusion in Dog plasma | in vivo | http://www.anaspec.com/products/product.asp?id=574 | None | Radiolabelled peptide was administered in rats and blood plasma was taken and analysed by HPLC. Brain level of radioactivity increased with time. | |||
| 6127205 | 1982 | Somatostatin 28 | 28 | Free | Free | Cyclic (C17-C28) | L | None | Ovine hypothalamus | Regulates the endocrine system and affects neurotransmission and cell proliferation | 30-45 minute | 20 µg | 2.8 ±0.3 | Dog blood plasma | SS Radioimmunoassay assay | Intravenous infusion in Dog plasma | in vivo | http://www.anaspec.com/products/product.asp?id=574 | None | When 50ng of SS14 was injected there is 85.1% decreasedportal venous blood flow was observed as compared to percentage of basal flow. | |||
| 6128770 | 1982 | Somatostatin 14 | 14 | Free | Free | Cyclic (C3-C14) | L | None | Ovine hypothalamus | Regulates the endocrine system and affects neurotransmission and cell proliferation | 1 hour | 1.7nmol | 2.4 | cat blood protease | Not mentioned | Intravenous infusion to cat plasma | in vivo | http://www.anaspec.com/products/product.asp?id=574 | None | When 100ng of SS28 is injected there is 73% decreased portal venous blood flow as compared to basal blood flow. | |||
| 6128770 | 1982 | Somatostatin 28 | 28 | Free | Free | Cyclic (C17-C28) | L | None | Ovine hypothalamus | Regulates the endocrine system and affects neurotransmission and cell proliferation | 1 hour | 4.8nmol | 6.1 | cat blood protease | Not mentioned | Intravenous infusion to cat plasma | in vivo | http://www.anaspec.com/products/product.asp?id=574 | None | Gastrin exocrine inhibitor assay were performed. 80 % gastric inhibition observed at 7ug/kg of peptide. | |||
| 6239307 | 1984 | Atrial Natriuretic peptide | 28 | Free | Free | Cyclic (C7-C23) | L | None | Human heart | Depressor and natriuretic activity | 2 hours | 1nmol | 30 | Rat blood proteases | RP-HPLC | Intravenous administered to Rat | in vivo | None | None | Gastric exocrine inhibitory assay was performed. 80 % inhibition observed at 8ug/kg body weight of peptide | |||
| 6239307 | 1984 | Atriopeptin 3 | 24 | Free | Free | Cyclic (C3-C19) | L | I125 radiolabeled | Human heart | Depressor and natriuretic activity | 2 hours | 1nmol | 2.5 | Rat blood proteases | RP-HPLC | Intravenous administered to Rat | in vivo | None | None | Time course depression is seen and Atropeptin 3 shows 2 time more depressor activity as compared to control alpha heart ANP. | |||
| 6291099 | 1982 | Cholecystokinin-4 (CCK4) | 4 | Free | Amidation | Linear | L | None | Deudenum of pig | Intestinal hormone | Not given | 50 µM | 13 | Human plasma proteases | HPLC | Human plasma | in vitro | None | None | Not reported | |||
| 6291099 | 1982 | Cholecystokinin-4 (CCK4) | 4 | Free | Amidation | Linear | L | None | Deudenum of pig | Intestinal hormone | Not given | 50 µM | <1 | Rat plasma protease | HPLC | Rat Plasma | in vitro | None | None | Not reported | |||
| 6291099 | 1982 | CCK7 (Cholecystokinin-7) | 7 | Free | Amidation | Linear | L | None | Deudenum of pig | Intestinal hormone | Not given | 50 µM | 2.5 | Human blood proteases | HPLC | Human plasma | in vitro | None | None | Not reported | |||
| 6291099 | 1982 | CCK8 (Cholecystokinin-8) | 8 | Free | Amidation | Linear | L | None | Deudenum of pig | Intestinal hormone | Not given | 50 µM | 18 | Human plasma proteases | HPLC | Human plasma | in vitro | None | None | Not reported | |||
| 6291099 | 1982 | CCK8 (Cholecystokinin-8) | 8 | Free | Amidation | Linear | L | Sulphation of Tyrosine residue at position 2 | Derivative of natural cholecytokinin | Intestinal hormone | Not given | 50 µM | 50 | Human plasma proteases | HPLC | Human plasma | in vitro | None | None | Not reported | |||
| 6291099 | 1982 | CCK8 (Cholecystokinin-8) | 8 | Free | Amidation | Linear | L | None | Deudenum of pig | Intestinal hormone | Not given | 50 µM | 5 | Rat plasma protease | HPLC | Rat Plasma | in vitro | None | None | Not reported | |||
| 6291099 | 1982 | CCK8 (Cholecystokinin-8) | 8 | Free | Amidation | Linear | L | Sulphation of Tyrosine residue at position 2 | Derivative of natural cholecytokinin | Intestinal hormone | Not given | 50 µM | 17 | Rat plasma protease | HPLC | Rat Plasma | in vitro | None | None | Not reported | |||
| 6291099 | 1982 | CCK9 (Cholecystokinin-9) | 9 | Free | Amidation | Linear | L | Sulphation of Tyrosine residue at position 3 | Derivative of natural cholecytokinin | Intestinal hormone | Not given | 50 µM | 2.7 | Human plasma proteases | HPLC | Human plasma | in vitro | None | None | Not reported | |||
| 6291099 | 1982 | CCK10 (Cholecystokinin-10) | 10 | Free | Amidation | Linear | L | Sulphation of tyrosine residue at position 4 | Derivative of natural cholecytokinin | Intestinal hormone | Not given | 50 µM | 30 | Human blood proteases | HPLC | Human plasma | in vitro | None | None | Not reported | |||
| 6291099 | 1982 | CCK10 (Cholecystokinin-10) | 10 | Free | Amidation | Linear | L | Sulphation of tyrosine residue at position 4 | Derivative of natural cholecytokinin | Intestinal hormone | Not given | 50 µM | 45 | Rat plasma protease | HPLC | Rat Plasma | in vitro | None | None | Not reported | |||
| 6344071 | 1983 | E.Coli leader peptide of tryptophan operon | 14 | Free | Free | Linear | L | None | E.coli trp operon | Regulatory peptide | Not given | Not mentioned | 03-Apr | Cell-free (S-30) extracts prepared from E. coli strain W3110 trpR tnaA2 AtrpEA2 rna | Radioactivity decay assay (3H) .Leader peptide is radiolabelled and then decay in radioactivity is measured. | Not reported | in vitro | None | None | Not reported | |||
| 6522442 | 1984 | Dermorphin | 7 | Free | Free | Linear | L | I125 radiolabeled | Frog skin | Opiod receptor agonist | 60 minute | 500 μg/kg | 1.3 | Rat blood proteases | Radioimmunoassay and HPLC | Intravenous injection into tail of rats | in vivo | http://www.anaspec.com/products/product.asp?id=450 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 76 μg | 16.2 (t1/2 fast) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 85 μg | 13.3 (t1/2 fast) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 75 μg | 12.4 (t1/2 fast) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 75 μg | 12.7 (t1/2 fast) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 90 μg | 5.6 (t1/2 fast) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 80 μg | 9.4 (t1/2 fast) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 80 μg | 11.6 (mean t1/2 fast) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 76 μg | 70.8 (t1/2 slow) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 85 μg | 49.5 (t1/2 slow) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 75 μg | 95.4 (t1/2 slow) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 75 μg | 90.8 (t1/2 slow) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 90 μg | 47.9 (t1/2 slow) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 80 μg | 83.5 (t1/2 slow) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6605972 | 1984 | Ovine corticotropic releasing factor | 41 | Free | Free | Linear | L | None | Paraventricular nucleus (PVN) of the hypothalamus | Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis | 0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min. | 80 μg | 73.0 (mean t1/2 slow) | Human blood plasma proteases | Radioimmunoassay and HPLC analysis | Intravenous administration to human plasma | in vivo | http://www.anaspec.com/products/product.asp?id=322 | None | Not reported | |||
| 6658706 | 1983 | 125I-labeled desamino-tyrosyl (DAT-FPA) FPA | 16 | Free | Free | Linear | L | DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T | Desaminotyrosine Fibrinopeptide derivative | Blood clotting | 5 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 30 (radioactivity) | Normal rabbit blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of normal rabbit | in vivo | http://search.anaspec.com/?keywords=fibrinopeptide | None | Not reported | |||
| 6658706 | 1983 | 125I-labeled desamino-tyrosyl (DAT-FPA) FPA | 16 | Free | Free | Linear | L | DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T | Desaminotyrosine Fibrinopeptide derivative | Blood clotting | 6 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 7 (radioactivity) | Normal rabbit blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of normal rabbit | in vivo | http://search.anaspec.com/?keywords=fibrinopeptide | None | Not reported | |||
| 6658706 | 1983 | 125I-labeled desamino-tyrosyl (DAT-FPA) FPA | 16 | Free | Free | Linear | L | DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T | Desaminotyrosine Fibrinopeptide derivative | Blood clotting | 7 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 30 (radioactivity) | Normal rabbit blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of normal rabbit | in vivo | http://search.anaspec.com/?keywords=fibrinopeptide | None | Not reported | |||
| 6658706 | 1983 | 125I-labeled desamino-tyrosyl (DAT-FPA) FPA | 16 | Free | Free | Linear | L | DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T | Desaminotyrosine Fibrinopeptide derivative | Blood clotting | 8 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 180 (radioactivity) | Normal rabbit blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of normal rabbit | in vivo | http://search.anaspec.com/?keywords=fibrinopeptide | None | Not reported | |||
| 6658706 | 1983 | Human Fibrinopeptide A (FPA) | 16 | Free | Free | Linear | L | None | N terminal end of the A-alpha chain of fibrinogen | Blood clotting | 9 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 30 | Normal rabbit blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of normal rabbit | in vivo | None | None | Not reported | |||
| 6658706 | 1983 | Human Fibrinopeptide A (FPA) | 16 | Free | Free | Linear | L | None | N terminal end of the A-alpha chain of fibrinogen | Blood clotting | 10 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 3.5 | Normal rabbit blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of normal rabbit | in vivo | None | None | Not reported | |||
| 6658706 | 1983 | Human Fibrinopeptide A (FPA) | 16 | Free | Free | Linear | L | None | N terminal end of the A-alpha chain of fibrinogen | Blood clotting | 11 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 15 | Normal rabbit blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of normal rabbit | in vivo | None | None | Not reported | |||
| 6658706 | 1983 | Human Fibrinopeptide A (FPA) | 16 | Free | Free | Linear | L | None | N terminal end of the A-alpha chain of fibrinogen | Blood clotting | 12 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 90 | Normal rabbit blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of normal rabbit | in vivo | None | None | Not reported | |||
| 6658706 | 1983 | 125I-labeled desamino-tyrosyl (DAT-FPA) FPA | 16 | Free | Free | Linear | L | DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T | Desaminotyrosine Fibrinopeptide derivative | Blood clotting | 2 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 30 (radioactivity) | Nephrectomized rabbits blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of nephrectomized rabbits | in vivo | None | None | Not reported | |||
| 6658706 | 1983 | 125I-labeled desamino-tyrosyl (DAT-FPA) FPA | 16 | Free | Free | Linear | L | DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T | Desaminotyrosine Fibrinopeptide derivative | Blood clotting | 3 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 7 (radioactivity) | Nephrectomized rabbits blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of nephrectomized rabbits | in vivo | None | None | Not reported | |||
| 6658706 | 1983 | Human Fibrinopeptide A (FPA) | 16 | Free | Free | Linear | L | None | N terminal end of the A-alpha chain of fibrinogen | Blood clotting | 4 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 30 | Nephrectomized rabbits blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of nephrectomized rabbits | in vivo | None | None | Not reported | |||
| 6658706 | 1983 | Human Fibrinopeptide A (FPA) | 16 | Free | Free | Linear | L | None | N terminal end of the A-alpha chain of fibrinogen | Blood clotting | 5 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120 min | Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA | 4 | Nephrectomized rabbits blood proteases | Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma. | Intravenous injection in lateral vein of nephrectomized rabbits | in vivo | http://search.anaspec.com/?keywords=fibrinopeptide | None | Not reported | |||
| 6736205 | 1984 | Gastrin releasing peptide | 27 | Free | Free | Linear | L | None | Porcine nonantral gastric juice | Stimulate release of gastrin | Not given | GRP I (0-30 min) bolus injection of 1.41 pmol kg-1, followed by an infusion of 0.12 pmol kg-1 x min- | 2.8 ±0.4 min | Human serum proteases | Radioimmunoassay | Human serum | in vivo | http://www.anaspec.com/products/product.asp?id=301 | None | Plasma gastrin concentration increased immediately after administration of peptide intravenously. After two doses of peptide(1.50pmol/kg) gastrin concentration found to be 1551pmol as compared to basal level of 370pmol. | |||
| 7418787 | 1979 | Lysine vasopressin | 9 | Free | Free | Cyclic (C1-C6) | L | None | Human Pituitary | Regulator of fluid and water balance | Not given | 0.2 mg | 47.4 (t1/2 of specific radioactivity) | None | Liquid scintillation spectrometer | Weakly acidic solution (pH 4.0, acetic acid) | in vitro | None | None | Not reported | |||
| 2147684 | 1990 | Glucagon(19-29) | 11 | Free | Free | Linear | L | None | Glucagon derivative | Growth Hormone | Not mentioned | 200pmol/2.5ml | <10 | Hepatic plasma membrane proteases | Radioimmunoassay and HPLC | Hepatic plasma membrane | in vitro | None | None | Inhibit calcium pump at 20% concentration | |||
| 2182027 | 1990 | Endothelin 1 (ET-l) | 21 | Free | Free | Linear | L | Labelled with I125 | Synthetic peptide with the sequence of human and porcine Endothelin 1 | Vasoconstrictiong peptide | 15sec-6min | 0.2pmol | 40 | Wistar rats blood protease | HPLC | Wistar rats | in vivo | None | None | Causes vasoconstriction | |||
| 4572061 | 1972 | Luteinizing Hormone Releasing Hormone(LHRH) | 10 | Free | Amidation | Linear | L | pGlu=pyroglutamic acid, Tritium labeling | Gonadotropic cells in the anterior pituitary gland | Behavior influencing hormones | 2 minutes | 1 .0 μCi | 6.97 ±0.4 | Female Sprague Dawley rats blood protease | Radioimmunoassay | Intarvenous administration to Female Sprague Dawley rats | in vivo | None | None | LH-RH acts on the anterior pituitary to evoke the release of LH | |||
| 3871610 | 1985 | Rat α1- proteinase inhibitor | 60 | Free | Free | Linear | L | Glycosylation | Rat serum | Protelytic activities regulating peptide | 5 minutes, 30 minutes, 1 hour, 4 hour and 7 hour | Not mentioned | 170 (for glycosylated α1- proteinase inhibitor) | Rat serum proteases | Radioimmunoassay | Wistar rats | in vivo | http://www.uniprot.org/uniprot/Q9JMK6 | None | Protect tissue against proteolytic attack by leukocyte elastase | |||
| 3871610 | 1985 | Rat α1- proteinase inhibitor | 60 | Free | Free | Linear | L | None | Rat serum | Protelytic activities regulating peptide | 5 minutes, 30 minutes, 1 hour, 4 hour and 7 hour | Not mentioned | 30 (for unglycosylated α1- proteinase inhibitor) | Rat serum proteases | Radioimmunoassay | Wistar rats | in vivo | http://www.uniprot.org/uniprot/Q9JMK6 | None | Protect tissue against proteolytic attack by leukocyte elastase | |||
| 6433008 | 1984 | TAP-144 | 10 | Free | Ethylamide | Linear | Mix | pGlu=pyroglutamic acid, des-Gly | LHRH derivative | Gonadotrophins secreting hormone | 10 days | 10μg/100g body wt | 32 (t1/2 terminal phase) | Rat serum proteases | Not mentioned | Subcutaneous administration to Sprague-Dawley rats | in vivo | None | None | Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration | |||
| 6433008 | 1984 | TAP-144 | 10 | Free | Ethylamide | Linear | Mix | pGlu=pyroglutamic acid, des-Gly | LHRH derivative | Gonadotrophins secreting hormone | 10 days | 1μg/100g body wt | 90.6 (t1/2 terminal phase) | Rat serum proteases | Not mentioned | Vaginal administration to Sprague-Dawley rats | in vivo | None | None | Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration | |||
| 6433008 | 1984 | TAP-144 | 10 | Free | Ethylamide | Linear | Mix | pGlu=pyroglutamic acid, des-Gly | LHRH derivative | Gonadotrophins secreting hormone | 10 days | 10μg/100g body wt | 109.8 (t1/2 terminal phase) | Rat serum proteases | Not mentioned | Vaginal administration to Sprague-Dawley rats | in vivo | None | None | Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration | |||
| 6433008 | 1984 | TAP-144 | 10 | Free | Ethylamide | Linear | Mix | pGlu=pyroglutamic acid, des-Gly | LHRH derivative | Gonadotrophins secreting hormone | 10 days | 100μg/100g body wt | 55.5 (t1/2 terminal phase) | Rat serum proteases | Not mentioned | Rectal administration to Sprague-Dawley rats | in vivo | None | None | Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration | |||
| 6433008 | 1984 | TAP-144 | 10 | Free | Ethylamide | Linear | Mix | pGlu=pyroglutamic acid, des-Gly | LHRH derivative | Gonadotrophins secreting hormone | 10 days | 100μg/100g body wt | 43.7 (t1/2 terminal phase) | Rat serum proteases | Not mentioned | Nasal administration to Sprague-Dawley rats | in vivo | None | None | Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration | |||
| 4327730 | 1971 | Purified Sheep Adrenocorticotropic Hormone (ACTH) | 39 | Free | Free | Linear | L | None | Sheep Adrenocorticotropic Hormone (ACTH) | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | 2U | 7.32 (steriodigenic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | http://www.genscript.com/peptide/RP11304-ACTH_1-39 | None | Shows activity of 80~180USP Units/mg | |||
| 4327730 | 1971 | ACTH analogue- 3 | 18 | Free | Amidation | Linear | L | None | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | 5 μg | 2.6 (steriodigenic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | 4286483 | None | No odification in the activity of ACTH analog-2 peptide | |||
| 4327730 | 1971 | ACTH analogue- 4 | 18 | Free | Amidation | Linear | L | βAla = Beta alanine | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | Not mentioned | 7.32 (steriodigenic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | 4286483 | None | Showed higher potencies than Native ACTH in all the method tested | |||
| 4327730 | 1971 | ACTH analogue- 5 | 18 | Free | Amidation | Linear | L | Ibu = α-aminoisobutyric acid | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | Not mentioned | 9.6 (steriodigenic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | 4286483 | None | The intravenous and intramuscular potencies of peptide V, Ibu1 ACTH (1-18) amide were 480-757U/mg, 4-5 times higher than the values for native hormone but subcutaneous potency was rather low (264U/mg) and in vitro potency was much lower (83U/mg) than the intravenous and intramuscular potencies. | |||
| 4327730 | 1971 | ACTH analogue- 6 | 18 | Free | Amidation | Linear | L | βAla = Beta alanine, Orn = Ornithine | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | Not mentioned | 10.06 (steriodigenic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | 4286483 | None | Showed an activity about 2/3 of that of the original Lys15 peptides IV | |||
| 4327730 | 1971 | Purified Sheep Adrenocorticotropic Hormone (ACTH) | 39 | Free | Free | Linear | L | None | Sheep Adrenocorticotropic Hormone (ACTH) | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | Not mentioned | 4.43 (lipolytic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | http://www.genscript.com/peptide/RP11304-ACTH_1-39 | None | Shows activity of 80~180USP Units/mg | |||
| 4327730 | 1971 | ACTH analogue- 3 | 18 | Free | Amidation | Linear | L | None | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | Not mentioned | 1.95 (lipolytic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | 4286483 | None | Shows activity less than ACTH | |||
| 4327730 | 1971 | ACTH analogue- 4 | 18 | Free | Amidation | Linear | L | βAla = Beta alanine | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | Not mentioned | 3.08 (lipolytic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | 4286483 | None | Shows activity less than ACTH | |||
| 4327730 | 1971 | ACTH analogue- 5 | 18 | Free | Amidation | Linear | L | Ibu = α-aminoisobutyric acid | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | Not mentioned | 3.32 (lipolytic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | 4286483 | None | Shows activity less than ACTH | |||
| 4327730 | 1971 | ACTH analogue- 6 | 18 | Free | Amidation | Linear | L | βAla = Beta alanine, Orn = Ornithine | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | Not mentioned | 4.53 (lipolytic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | 4286483 | None | Shows activity less than ACTH | |||
| 4327730 | 1971 | ACTH analogue- 7 | 18 | Free | Amidation | Linear | L | Ibu = α-aminoisobutyric acid | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1/2, 1, 2, 4, 8, and 16min | Not mentioned | 6 (lipolytic activity t1/2) | Rat blood proteases | Not mentioned | Intravenously injected to rat | in vivo | 4286483 | None | Shows activity more than ACTH | |||
| 4327730 | 1971 | Purified Sheep Adrenocorticotropic Hormone (ACTH) | 39 | Free | Free | Linear | L | None | Sheep Adrenocorticotropic Hormone (ACTH) | Steroidogenic peptides | 1,2,3 and 4 hours | 200 mU | 59.22 (lipolytic activity t1/2) | Rat plasma proteases | Not mentioned | Rat plasma | in vitro | http://www.genscript.com/peptide/RP11304-ACTH_1-39 | None | Not mentionedtive ACTH shows similar activity to rat and rabbit fats when compared in terms of the minimal effective dose (rat = 6*10-6mg/50mg tissue and rabbit = 5*10-6mg/50mg tissue) | |||
| 4327730 | 1971 | ACTH analogue- 3 | 18 | Free | Amidation | Linear | L | None | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | Not mentioned | 30 (lipolytic activity t1/2) | Rat plasma proteases | Not mentioned | Rat plasma | in vitro | 4286483 | None | Showed much higher activity in rabbit fat than in rat fat (rat = 6*10-6mg/50mg tissue and rabbit = 0.4*10-6mg/50mg tissue) | |||
| 4327730 | 1971 | ACTH analogue- 4 | 18 | Free | Amidation | Linear | L | βAla = Beta alanine | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | 20 μg | 35.4 (lipolytic activity t1/2) | Rat plasma proteases | Not mentioned | Rat plasma | in vitro | 4286483 | None | Showed much higher activity in rabbit fat than in rat fat (rat = 0.6*10-6mg/50mg tissue and rabbit = 0.07*10-6mg/50mg tissue) | |||
| 4327730 | 1971 | ACTH analogue- 5 | 18 | Free | Amidation | Linear | L | Ibu = α-aminoisobutyric acid | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | 20 μg | 32.43 (lipolytic activity t1/2) | Rat plasma proteases | Not mentioned | Rat plasma | in vitro | 4286483 | None | Showed much higher activity in rabbit fat than in rat fat (rat = 0.2*10-6mg/50mg tissue and rabbit = 0.002*10-6mg/50mg tissue) | |||
| 4327730 | 1971 | ACTH analogue- 6 | 18 | Free | Amidation | Linear | L | βAla = Beta alanine, Orn = Ornithine | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | Not mentioned | 76.2 (lipolytic activity t1/2) | Rat plasma proteases | Not mentioned | Rat plasma | in vitro | 4286483 | None | Similar or higher activity in rat than in rabbit (rat = 0.4*10-6mg/50mg tissue and rabbit = 0.1*10-6mg/50mg tissue | |||
| 4327730 | 1971 | ACTH analogue- 7 | 18 | Free | Amidation | Linear | L | Ibu = α-aminoisobutyric acid | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | Not mentioned | 80.63 (lipolytic activity t1/2) | Rat plasma proteases | Not mentioned | Rat plasma | in vitro | 4286483 | None | Similar or higher activity in rat than in rabbit (rat = 0.06*10-6mg/50mg tissue and rabbit = 0.5*10-6mg/50mg tissue | |||
| 4327730 | 1971 | ACTH analogue- 8 | 18 | Free | Amidation | Linear | Mix | βAla = Beta alanine, Orn = Ornithine | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | Not mentioned | 88.12 (lipolytic activity t1/2) | Rat plasma proteases | Not mentioned | Rat plasma | in vitro | 4286483 | None | Similar or higher activity in rat than in rabbit (rat = 0.07*10-6mg/50mg tissue and rabbit = 0.2*10-6mg/50mg tissue | |||
| 4327730 | 1971 | Purified Sheep Adrenocorticotropic Hormone (ACTH) | 39 | Free | Free | Linear | L | None | Sheep Adrenocorticotropic Hormone (ACTH) | Steroidogenic peptides | 1,2,3 and 4 hours | 200 mU | 250.87 (lipolytic activity t1/2) | Rat muscle proteases | Not mentioned | Rat muscle slices | in vitro | http://www.genscript.com/peptide/RP11304-ACTH_1-39 | None | Not mentionedtive ACTH shows similar activity to rat and rabbit fats when compared in terms of the minimal effective dose (rat = 6*10-6mg/50mg tissue and rabbit = 5*10-6mg/50mg tissue) | |||
| 4327730 | 1971 | ACTH analogue- 3 | 18 | Free | Amidation | Linear | L | None | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | Not mentioned | 42.6 (lipolytic activity t1/2) | Rat muscle proteases | Not mentioned | Rat muscle slices | in vitro | 4286483 | None | Showed much higher activity in rabbit fat than in rat fat (rat = 6*10-6mg/50mg tissue and rabbit = 0.4*10-6mg/50mg tissue) | |||
| 4327730 | 1971 | ACTH analogue- 4 | 18 | Free | Amidation | Linear | L | βAla = Beta alanine | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | 20 μg | 88.2 (lipolytic activity t1/2) | Rat muscle proteases | Not mentioned | Rat muscle slices | in vitro | 4286483 | None | Showed much higher activity in rabbit fat than in rat fat (rat = 0.6*10-6mg/50mg tissue and rabbit = 0.07*10-6mg/50mg tissue) | |||
| 4327730 | 1971 | ACTH analogue- 5 | 18 | Free | Amidation | Linear | L | Ibu = α-aminoisobutyric acid | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | 20 μg | 122.88 (lipolytic activity t1/2) | Rat muscle proteases | Not mentioned | Rat muscle slices | in vitro | 4286483 | None | Showed much higher activity in rabbit fat than in rat fat (rat = 0.2*10-6mg/50mg tissue and rabbit = 0.002*10-6mg/50mg tissue) | |||
| 4327730 | 1971 | ACTH analogue- 6 | 18 | Free | Amidation | Linear | L | βAla = Beta alanine, Orn = Ornithine | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | Not mentioned | 102.62 (lipolytic activity t1/2) | Rat muscle proteases | Not mentioned | Rat muscle slices | in vitro | 4286483 | None | Similar or higher activity in rat than in rabbit (rat = 0.4*10-6mg/50mg tissue and rabbit = 0.1*10-6mg/50mg tissue | |||
| 4327730 | 1971 | ACTH analogue- 7 | 18 | Free | Amidation | Linear | L | Ibu = α-aminoisobutyric acid | Octadecapeptide analogues of ACTH | Steroidogenic peptides | 1,2,3 and 4 hours | Not mentioned | 261.78 (lipolytic activity t1/2) | Rat muscle proteases | Not mentioned | Rat muscle slices | in vitro | 4286483 | None | Similar or higher activity in rat than in rabbit (rat = 0.06*10-6mg/50mg tissue and rabbit = 0.5*10-6mg/50mg tissue | |||
| 2162275 | 1990 | VIP (Vasoactive intestinal peptide) | 28 | Acetylation | Amidation | Linear | L | None | Neuropeptide derived from Prepro-VIP | Vasodilator | Not mentioned | 5 pmol min-1 kg-1 | 0.8 | Human plasma proteases | Radioimmunoassay | Human plasma | in vivo | None | None | It increase heart rate | |||
| 2162275 | 1990 | PHM (Peptide histidine methionine) | 27 | Free | Amidation | Linear | L | None | Peptide derived from Prepro-VIP | Vasodilator | Not mentioned | 5 pmol min-1 kg-1 | 6.5 | Human plasma proteases | Radioimmunoassay | Human plasma | in vivo | None | None | It increase heart rate | |||
| 2162275 | 1990 | PHV (Peptide histidine valine) | 42 | Free | Free | Linear | L | None | Peptide derived from Prepro-VIP | Vasodilator | Not mentioned | 5 pmol min-1 kg-1 | 37.5 | Human plasma proteases | Radioimmunoassay | Human plasma | in vivo | None | None | It increases heart rate but not significantly | |||
| 2896343 | 1988 | GRF(1-29)-NH2 (Growth regulating factor) | 29 | Free | Amidation | Linear | L | None | Growth regulating factor | Release growth hormone | Blood collected 1-90 minutes after peptide injection | 20μg/200μl | 6.2 ±0.7 | Rat plasma proteases | Radioimmunoassay | Rat plasma (i/v and s/c route of injection) | in vivo | None | None | Relative potency for GH releasing activity = 100% | |||
| 2896343 | 1988 | [D-Ala2]-GRF(1-29)-NH2 (Growth regulating factor) | 29 | Free | Amidation | Linear | Mix | None | GRF-1 analogs | Release growth hormone | Blood collected 1-90 minutes after peptide injection | 20μg/200μl | 6.6 ±0.4 | Rat plasma proteases | Radioimmunoassay | Rat plasma (i/v and s/c route of injection) | in vivo | None | None | Relative potency for GH releasing activity = 5146% | |||
| 2896343 | 1988 | [D-Asp3]-GRF(1-29)-NH2 (Growth regulating factor) | 29 | Free | Amidation | Linear | Mix | None | GRF-1 analogs | Release growth hormone | Blood collected 1-90 minutes after peptide injection | 20μg/200μl | 5.9 ±0.8 | Rat plasma proteases | Radioimmunoassay | Rat plasma (i/v and s/c route of injection) | in vivo | None | None | Relative potency for GH releasing activity = 670% | |||
| 2896343 | 1988 | lD-Asn8]-GRF(1-29)-NH2 (Growth regulating factor) | 29 | Free | Amidation | Linear | Mix | None | GRF-1 analogs | Release growth hormone | Blood collected 1-90 minutes after peptide injection | 20μg/200μl | 6.9 ±0.5 | Rat plasma proteases | Radioimmunoassay | Rat plasma (i/v and s/c route of injection) | in vivo | None | None | Relative potency for GH releasing activity = 221% | |||
| 2896343 | 1988 | [D-Tyr10]-GRF(1-29)-NH2 (Growth regulating factor) | 29 | Free | Amidation | Linear | Mix | None | GRF-1 analogs | Release growth hormone | Blood collected 1-90 minutes after peptide injection | 20μg/200μl | 4.7 ±0.8 | Rat plasma proteases | Radioimmunoassay | Rat plasma (i/v and s/c route of injection) | in vivo | None | None | Relative potency for GH releasing activity = 230% | |||
| 2896343 | 1988 | Ac-[D-Tyr1,D-AIa2]GRF(1-29)-NH2 (Growth regulating factor) | 29 | Acetylation | Amidation | Linear | Mix | None | GRF-1 analogs | Release growth hormone | Blood collected 1-90 minutes after peptide injection | 20μg/200μl | 7.4 ±0.5 | Rat plasma proteases | Radioimmunoassay | Rat plasma (i/v and s/c route of injection) | in vivo | None | None | Relative potency for GH releasing activity = 2817% | |||
| 2940625 | 1986 | [D-Trp6]-LHRH (Luteinizing hormone-releasing hormone) | 10 | Free | Amidation | Linear | Mix | Pyr=Pyro-glutamic acid | LHRH (Luteinizing hormone-releasing hormone) derivative | Release Luteinizing hormone | Blood collected 1-240 minutes after peptide infused | 100 µg/ml | >10 (alpha t1/2) | Dog plasma proteases | HPLC | Two male Beagle dogs plasma (Dose s/c injected) | in vivo | None | None | Not reported | |||
| 2940625 | 1986 | [D-Trp6]-LHRH (Luteinizing hormone-releasing hormone) | 10 | Free | Amidation | Linear | Mix | Pyr=Pyro-glutamic acid | LHRH (Luteinizing hormone-releasing hormone) derivative | Release Luteinizing hormone | Blood collected 1-240 minutes after peptide infused | 100 µg/ml | >84 (beta t1/2) | Dog plasma proteases | HPLC | Two male Beagle dogs plasma (Dose s/c injected) | in vivo | None | None | Not reported | |||
| 2942845 | 1986 | ANF (Ser99-Tyr126) (Atrial natriuretic factor ) | 28 | Free | Free | Cyclic (C7-C23) | L | Radioiodinated peptide at Tyr | Atrial natriuretic factor derivative | Natriuretic, diuretic and vasorelaxant peptide | Blood collected 5second-5 minutes after peptide injected | 60mg/kg | 16.8 ±0.9 | Rat plasma proteases | RP-HPLC | Male Sprague-Dawley rats plasma (Dose i/p injected) | in vivo | None | None | IC50=59pM, Inhibition of aldosterone production | |||
| 2942845 | 1986 | ANF (Arg101-Tyr126) (Atrial natriuretic factor ) | 26 | Free | Free | Cyclic (C5-C21) | L | Radioiodinated peptide at Tyr | Atrial natriuretic factor derivative | Natriuretic, diuretic and vasorelaxant peptide | Blood collected 5second-5 minutes after peptide injected | 60mg/kg | 17.1 ±1.5 | Rat plasma proteases | RP-HPLC | Male Sprague-Dawley rats plasma (Dose i/p injected) | in vivo | None | None | IC50=204pM, Inhibition of aldosterone production | |||
| 2942845 | 1986 | ANF (Ser103-Tyr126) (Atrial natriuretic factor ) | 24 | Free | Free | Cyclic (C3-C19) | L | Radioiodinated peptide at Tyr | Atrial natriuretic factor derivative | Natriuretic, diuretic and vasorelaxant peptide | Blood collected 5second-5 minutes after peptide injected | 60mg/kg | 22.0 ±4.5 | Rat plasma proteases | RP-HPLC | Male Sprague-Dawley rats plasma (Dose i/p injected) | in vivo | None | None | IC50=276pM, Inhibition of aldosterone production | |||
| 2942845 | 1986 | ANF (Ser99-Tyr126) (Atrial natriuretic factor ) | 28 | Free | Free | Cyclic (C7-C23) | L | Radioiodinated peptide at Tyr | Atrial natriuretic factor derivative | Natriuretic, diuretic and vasorelaxant peptide | Blood collected 5second-5 minutes after peptide injected | 60mg/kg | 25.2 ±6.1 | Rat plasma proteases | RP-HPLC | Male Sprague-Dawley rats (nephrectomized rat) plasma (Dose i/p injected) | in vivo | None | None | Not reported | |||
| 2942845 | 1986 | ANF (Ser99-Tyr126) (Atrial natriuretic factor ) | 28 | Free | Free | Cyclic (C7-C23) | L | Radioiodinated peptide at Tyr | Atrial natriuretic factor derivative | Natriuretic, diuretic and vasorelaxant peptide | Blood collected 5second-5 minutes after peptide injected | 60mg/kg | 16.3 ±1.2 | Rat plasma proteases | RP-HPLC | Male Sprague-Dawley rats (hepatectomized rat) plasma (Dose i/p injected) | in vivo | None | None | Not reported | |||
| 2942845 | 1986 | ANF (Ser99-Tyr126) (Atrial natriuretic factor ) | 28 | Free | Free | Cyclic (C7-C23) | L | Radioiodinated peptide at Tyr | Atrial natriuretic factor derivative | Natriuretic, diuretic and vasorelaxant peptide | Blood collected 5second-5 minutes after peptide injected | 60mg/kg | 19.4 ±3.5 | Rat plasma proteases | RP-HPLC | Male Sprague-Dawley rats (both nephrectomized & hepatectomized rat) plasma (Dose i/p injected) | in vivo | None | None | Not reported | |||
| 2953516 | 1987 | rANP (Recombinant Atrial natriuretic peptide ) | 26 | Free | Free | Cyclic (C5-C21) | L | None | Atrial natriuretic factor | Natriuretic, diuretic and vasorelaxant peptide | Blood collected 0.2-2 hours after peptide injection | 1 μg/min dose | 4.5 | Human plasma proteases | Radioimmunoassay | Human plasma | in vivo | None | None | ANP induced dose-related effects on systemic and renal hemodynamic, as well as electrolyte excretion | |||
| 2966345 | 1988 | rANF(Asn1-Arg98) [Rat atrial natriuretic factor] | 98 | Free | Free | Linear | L | Radioiodinated peptide at Tyr-4 | Rat ANF derivative [Rat atrial natriuretic factor] | Natriuretic, diuretic and vasorelaxant peptide | Not mentioned | 10 X106 CPM | 54.8 ±3.9(2nd component) | Rat plasma proteases | Radioimmunoassay | Male Sprague-Dawley rats plasma | in vivo | http://www.uniprot.org/uniprot/P01161 | None | Not reported | |||
| 2966345 | 1988 | rANF(Asn1-Arg98) [Rat atrial natriuretic factor] | 98 | Free | Free | Linear | L | Radioiodinated peptide at Tyr-4 | Rat ANF derivative [Rat atrial natriuretic factor] | Natriuretic, diuretic and vasorelaxant peptide | Not mentioned | 10 X106 CPM | 2.5 ±0.3(1st compent) | Rat plasma proteases | Radioimmunoassay | Male Sprague-Dawley rats plasma | in vivo | http://www.uniprot.org/uniprot/P01162 | None | Not reported | |||
| 2988919 | 1985 | r/hCRF(Human/rat corticotropin-releasing factor) | 41 | Free | Free | Linear | L | None | Peptide hormone secreted by hypothalamus | Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH) | Blood samples collected at 1-180 minutes after peptide injection | 10 µg/kg peptide injected to rhesus monkey | 4.0 ±1.2 (t1/2fast) | Rhesus monkey proteases | Radioimmunoassay | Rhesus monkey plasma | in vivo | None | None | ACTH increased by 1035 ± 226 %, cortisol increased by 123 ± 34% on 10 µg/kg dose | |||
| 2988919 | 1985 | r/hCRF(Human/rat corticotropin-releasing factor) | 41 | Free | Free | Linear | L | None | Peptide hormone secreted by hypothalamus | Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH) | Blood samples collected at 1-180 minutes after peptide injection | 100 µg/kg peptide injected to rhesus monkey | 1.5 ±0.5 (t1/2fast) | Rhesus monkey proteases | Radioimmunoassay | Rhesus monkey plasma | in vivo | None | None | ACTH increased by 1858 ± 452 %, cortisol increased by 231 ± 28% on 10 µg/kg dose | |||
| 2988919 | 1985 | oCRF(Ovine corticotropin-releasing factor) | 41 | Free | Free | Linear | L | None | Peptide hormone secreted by hypothalamus | Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH) | Blood samples collected at 1-180 minutes after peptide injection | 1 µg/kg peptide injected to rhesus monkey | 3.6 ±1.1 (t1/2 fast) | Rhesus monkey proteases | Radioimmunoassay | Rhesus monkey plasma | in vivo | None | None | ACTH increased by 161 ± 40 %, cortisol increased by 78 ± 22 % on 10 µg/kg dose | |||
| 2988919 | 1985 | r/hCRF(Human/rat corticotropin-releasing factor) | 41 | Free | Free | Linear | L | None | Peptide hormone secreted by hypothalamus | Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH) | Blood samples collected at 1-180 minutes after peptide injection | 10 µg/kg peptide injected to rhesus monkey | 29.0 ±2.0(t1/2 slow) | Rhesus monkey proteases | Radioimmunoassay | Rhesus monkey plasma | in vivo | None | None | ACTH increased by 1858 ± 452 %, cortisol increased by 123 ± 28% on 10 µg/kg dose | |||
| 2988919 | 1985 | r/hCRF(Human/rat corticotropin-releasing factor) | 41 | Free | Free | Linear | L | None | Peptide hormone secreted by hypothalamus | Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH) | Blood samples collected at 1-180 minutes after peptide injection | 100 µg/kg peptide injected to rhesus monkey | 32.7 ±10.1 (t1/2 slow) | Rhesus monkey proteases | Radioimmunoassay | Rhesus monkey plasma | in vivo | None | None | ACTH increased by 1858 ± 452 %, cortisol increased by 231 ± 28% on 10 µg/kg dose | |||
| 2988919 | 1985 | oCRF(Ovine corticotropin-releasing factor) | 41 | Free | Free | Linear | L | None | Peptide hormone secreted by hypothalamus | Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH) | Blood samples collected at 1-180 minutes after peptide injection | 1 µg/kg peptide injected to rhesus monkey | 44.3 +/= 6.7 (t1/2 slow) | Rhesus monkey proteases | Radioimmunoassay | Rhesus monkey plasma | in vivo | None | None | ACTH increased by 161 ± 40 %, cortisol increased by 78 ± 22 % on 10 µg/kg dose | |||
| 2970910 | 1988 | Naferlin | 10 | Free | Amidation | Linear | L | pE=Pyro-glutamate, D-alanin= 3-(2Naphthyl)-D-alanine | GnRH (Gonadotropin releasing hormone) agonist | It decreases pituitary secretion of the gonadotropins | Not mentioned | 400 µg | 2.3 ±0.2 | Human serum proteases | Radioimmunoassay | Subcutaneous route of injection in human serum | in vivo | None | None | Not reported | |||
| 2970910 | 1988 | Naferlin | 10 | Free | Amidation | Linear | L | pE=Pyro-glutamate, D-alanin= 3-(2Naphthyl)-D-alanine | GnRH (Gonadotropin releasing hormone) agonist | It decreases pituitary secretion of the gonadotropins | Not mentioned | 304 ± 2.2 µg | 2.7 ±0.2 | Human serum proteases | Radioimmunoassay | Nasal route of injection in human serum | in vivo | None | None | Not reported | |||
| 3147901 | 1988 | Oxyntomodulin | 37 | Free | Free | Linear | L | None | Synthetic derived from proglucagon, identified in extracts from porcine small intestinal mucosa | GLP-1-GCGR (glucagon) agonist | Blood samples collected at 1-5 hourss after peptide injection | 100- 400ng/kg/h | 12 ±1 | Human plasma proteases | Radioimmunoassay | Human plasma (Dose i/v injected) | in vivo | http://www.glucagon.com/oxyntomodulin.html | None | The acid secretion increased during the first 90 rnin of pentagastrin infusion from 1 - 2 meq H+/15 rnin to a plateau of 5-6 meq H+/15 min | |||
| 3215483 | 1988 | MET-enkephalin (Methionine-enkephalin) | 5 | Free | Free | Linear | L | None | Enkephalin | Neurotransmitter | 37 °C for 1-180 minutes | 300pg (pooled platelet-poor plasma) | 12.8 | Human plasma proteases | TLC (Thin-layer chromatography) | Human plasma | in vitro | None | None | Not reported | |||
| 3215483 | 1988 | LEU-enkephalin (Leucine-enkephalin) | 5 | Free | Free | Linear | L | None | Enkephalin | Neurotransmitter | 37 °C for 1-180 minutes | 300pg (pooled platelet-poor plasma) | 7 | Human plasma proteases | TLC (Thin-layer chromatography) | Human plasma | in vitro | None | None | Not reported | |||
| 3261772 | 1988 | hCGRP(Human Calcitonin gene-related peptide) | 37 | Free | Amidation | Cyclic (C2-C7) | L | None | Alernative spliced product of calcitonon produced by thyroid gland | Vasodilator and cause tumor hypoxia | Blood collected-10 to 90 minutes after peptide infusion | 5pmol/kg | 3.6 ±0.3 (Half life of 1st phase) | Sheep plasma proteases | Radioimmunoassay, RP-HPLC | Merino-Corriedale cross ewes (sheep) plasma | in vivo | None | None | Not reported | |||
| 3261772 | 1988 | hCGRP(Human Calcitonin gene-related peptide) | 37 | Free | Amidation | Cyclic (C2-C7) | L | None | Alernative spliced product of calcitonon produced by thyroid gland | Vasodilator and cause tumor hypoxia | Blood collected-10 to 90 minutes after peptide infusion | 5pmol/kg | 13.6 ±1.0(Half life of 1st phase) | Sheep plasma proteases | Radioimmunoassay, RP-HPLC | Merino-Corriedale cross ewes (sheep) plasma | in vivo | None | None | Not reported | |||
| 3360050 | 1988 | BW443 (Enkephalin Analogue) | 5 | Free | Amidation | Linear | Mix | 4 nitro groups linked to Phenylalanine (phe) at 4th position | Enkephalin analogue | Antinociceptive and antitussive | Blood collected 10 minutes to 8 hours after peptide infusion | 0.1-10 µg/kg peptide | 2.0 ±0.4 | Proteases from Human plasma | Radioimmunoassay | Human plasma | in vivo | None | None | Not reported | |||
| 3379352 | 1988 | IGF-1 (Insulin-like growth factor-I) | 70 | Free | Free | Linear | L | Labelled with 125I | Purified from bovine colostrum | Mediates growth and development | Blood collected 10 minutes to 30 hours after peptide infusion | 10mM/L | 6.0-7.0 | Lamb plasma proteases | Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity | Eight merino lambs plasma | in vivo | None | None | Not reported | |||
| 3379352 | 1988 | Reduced IGF-1(Free form) (Insulin-like growth factor-I) | 70 | Free | Free | Linear | L | Labelled with 125I, Disulphide bond is reduced | Bovine IGF-1 | Mediates growth and development | Blood collected 10 minutes to 30 hours after peptide infusion | 10mM/L | 0.8 | Lamb plasma proteases | Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity | Eight merino lambs plasma | in vivo | None | None | Not reported | |||
| 3379352 | 1988 | Reduced IGF-1(bound form) (Insulin-like growth factor-I) | 70 | Free | Free | Linear | L | Labelled with 125I, Disulphide bond is reduced | Bovine IGF-1 | Mediates growth and development | Blood collected 10 minutes to 30 hours after peptide infusion | 10mM/L | 6 | Lamb plasma proteases | Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity | Eight merino lambs plasma | in vivo | None | None | Not reported | |||
| 3379352 | 1988 | S-CM IGF-1 (Insulin-like growth factor-I) | 70 | Free | Free | Linear | L | S-CM=S-carboxymethylated | Bovine IGF-1 | Mediates growth and development | Blood collected 10 minutes to 30 hours after peptide infusion | 10mM/L | 0.8-0.9 | Lamb plasma proteases | Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity | Eight merino lambs plasma | in vivo | None | None | Not reported | |||
| 3601235 | 1987 | Porcine NPY (Neuropeptide Y) | 36 | Free | Amidation | Linear | L | None | Neuropeptide | Acts as a neurotransmitter | Blood collected 1 to 90 minutes after peptide infusion | 06-10nM/kg | ~ 20 (20-28) | Dog plasma proteases | Radioimmunoassay | Six mongrel dogs plasma (Dose i/v injected) | in vivo | None | None | Not reported | |||
| 3492729 | 1986 | MET-enkephalin (Methionine-enkephalin) | 5 | Free | Free | Linear | L | None | Enkephalin | Neurotransmitter | Blood collected 5-60 minutes after peptide infused | 1-20mM | <2 | Proteases from rhesus monkey plasma | RP-HPLC | Rhesus monkey plasma | in vitro | None | None | Not reported | |||
| 3768731 | 1986 | DSIP (Delta sleep inducing peptide) | 9 | Free | Free | Linear | L | None | Neuropeptide secreted from hypothamus | Stress reliever, stimulates LH, somatostatin | Blood collected 2-60 minutes after peptide injected | 0.1mg/Kg | 7.24 ±0.77 | Proteases from dog plasma | Radioimmunoassay | Mongrel dog plasma(Dose i/v injected) | in vivo | None | None | Not reported | |||
| 3768731 | 1986 | des-Trp-DSIP | 8 | Free | Free | Linear | L | None | DSIP analogue | Anticarcinogenic | Blood collected 2-60 minutes after peptide injected | 0.1mg/Kg | 7.55 ±0.52 | Proteases from dog plasma | Radioimmunoassay | Mongrel dog plasma(Dose i/v injected) | in vivo | None | None | Not reported | |||
| 3768731 | 1986 | D-Ala3-DSIP | 9 | Free | Free | Linear | Mix | None | DSIP analogue | Anticarcinogenic | Blood collected 2-60 minutes after peptide injected | 0.1mg/Kg | 8.19 ±0.30 | Proteases from dog plasma | Radioimmunoassay | Mongrel dog plasma(Dose i/v injected) | in vivo | None | None | Not reported | |||
| 3768731 | 1986 | D-Ala4-DSIP | 9 | Free | Free | Linear | Mix | None | DSIP analogue | Anticarcinogenic | Blood collected 2-60 minutes after peptide injected | 0.1mg/Kg | 12.9 ±0.83 | Proteases from dog plasma | Radioimmunoassay | Mongrel dog plasma(Dose i/v injected) | in vivo | None | None | Not reported | |||
| 3768731 | 1986 | D-Ala4-DSIP-NH2 | 9 | Free | Amidation | Linear | Mix | None | DSIP analogue | Anticarcinogenic | Blood collected 2-60 minutes after peptide injected | 0.1mg/Kg | 10.2 ±0.69 | Proteases from dog plasma | Radioimmunoassay | Mongrel dog plasma(Dose i/v injected) | in vivo | None | None | Not reported | |||
| 3924685 | 1985 | hGRF-1(1-40) (Human growth regulating factor) | 40 | Free | Amidation | Linear | L | None | Human growth regulating factor | Release growth hormone | Blood collected 60-240 minutes after peptide injection | 5 µg/200ul | 57.3 ±1.5 (beta or elimination half life) | Rat plasma proteases | Radioimmunoassay | (Dose i/v injected)Rat plasma | in vivo | None | None | Not reported | |||
| 3924685 | 1985 | hGRF-1(1-40) (Human growth regulating factor) | 40 | Free | Amidation | Linear | L | None | Human growth regulating factor | Release growth hormone | Blood collected 60-240 minutes after peptide injection | 5 µg/200ul | 3.2 ±0.2 (alpha or distribution half life) | Rat plasma proteases | Radioimmunoassay | (Dose i/v injected)Rat plasma | in vivo | None | None | Not reported | |||
| 2156886 | 1990 | Porcine 125I-BNP(1-26) | 26 | Free | Free | Cyclic (C4-C20) | L | Tyr is Iodinated (125I) | Porcine brain and heart | Natriuretic and vasodilator | Blood collected 2-270 minutes after peptide injection | 2 pmol/kg peptide infused | 3.1 | Proteases from Human plasma | Radioimmunoassay | Human plasma | in vivo | None | None | PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP | |||
| 2175178 | 1990 | Porcine 125I-BNP(1-26) | 26 | Free | Free | Cyclic (C4-C20) | L | Tyr is Iodinated (125I) | Porcine brain and heart | Natriuretic and vasodilator | Blood collected 2-270 minutes after peptide injection | 0.17-0.25 Mbeq peptide infused | 1.23 ±0.35 | Rat plasma proteases | HPLC | Rat plasma | in vivo | None | None | PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP | |||
| 2175178 | 1990 | Porcine 125I-BNP(1-26) | 26 | Free | Free | Cyclic (C4-C20) | L | Tyr is Iodinated (125I) | Porcine brain and heart | Natriuretic and vasodilator | Blood collected 2-270 minutes after peptide injection | 0.17-0.25 Mbeq peptide+ captoril(ACE inhibitor) infused | 6.99 ±0.34 | Rat plasma proteases | HPLC | Rat plasma | in vivo | None | None | PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP | |||
| 2175178 | 1990 | Porcine 125I-BNP(1-26) | 26 | Free | Free | Cyclic (C4-C20) | L | Tyr is Iodinated (125I) | Porcine brain and heart | Natriuretic and vasodilator | Blood collected 2-270 minutes after peptide injection | 0.17-0.25 Mbeq peptide+phosphoramidon, a specific E-24.11 inhibitor infused | 11.8 ±0.49 | Rat plasma proteases | HPLC | Rat plasma | in vivo | None | None | PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP | |||
| 2175178 | 1990 | Porcine 125I-BNP(1-26) | 26 | Free | Free | Cyclic (C4-C20) | L | Tyr is Iodinated (125I) | Porcine brain and heart | Natriuretic and vasodilator | Blood collected 2-270 minutes after peptide injection | 0.17-0.25 Mbeq peptide+phosphoramidon, a specific E-24.11 inhibitor +captoril(ACE inhibitor infused | 14.3 ±0.48 | Rat plasma proteases | HPLC | Rat plasma | in vivo | None | None | PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP | |||
| 2175178 | 1990 | Porcine 125I-BNP(1-26) | 26 | Free | Free | Cyclic (C4-C20) | L | Tyr is Iodinated (125I) | Porcine brain and heart | Natriuretic and vasodilator | Blood collected 2-270 minutes after peptide injection | 1.5 Kbeq peptide | 4.6 ±0.1 | Proteases from Rat serum | HPLC | Rat Serum | in vitro | None | None | PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP | |||
| 2175178 | 1990 | Porcine 125I-BNP(1-26) | 26 | Free | Free | Cyclic (C4-C20) | L | Tyr is Iodinated (125I) | Porcine brain and heart | Natriuretic and vasodilator | Blood collected 2-270 minutes after peptide injection | 1.5 Kbeq peptide+ captoril(ACE inhibitor | 8.3 ±0.3 | Proteases from Rat serum | HPLC | Rat Serum | in vitro | None | None | PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP | |||
| 2175178 | 1990 | Porcine 125I-BNP(1-26) | 26 | Free | Free | Cyclic (C4-C20) | L | Tyr is Iodinated (125I) | Porcine brain and heart | Natriuretic and vasodilator | Blood collected 2-270 minutes after peptide injection | 1.5 Kbeq peptide+phosphoramidon, a specific E-24.11 inhibitor infuse | 5.6 ±0.2 | Proteases from Rat serum | HPLC | Rat Serum | in vitro | None | None | PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP | |||
| 2175178 | 1990 | Porcine 125I-BNP(1-26) | 26 | Free | Free | Cyclic (C4-C20) | L | Tyr is Iodinated (125I) | Porcine brain and heart | Natriuretic and vasodilator | Blood collected 2-270 minutes after peptide injection | 1.5 Kbeq peptide+phosphoramidon, a specific E-24.11 inhibitor +captoril(ACE inhibitor infused | 9.9 ±0.4 | Proteases from Rat serum | HPLC | Rat Serum | in vitro | None | None | PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP | |||
| 2298867 | 1990 | Antide(Nal-Lys) | 10 | Acetylation | Amidation | Linear | Mix | None | Nal-Lys GnRH antagonist | Regulates or inhibits LH release or gonadotropins | Blood collected upto 30 days after peptide injection | 3.5mg/kg injected i/v | 6.5 | Proteases from OVX monkey serum | Radioactive assay | (Dose i/v injected)OVX monkey Serum | in vivo | None | None | Gonadotropin inhibition;Following sc or iv Antide injection, peripheral Luteinizing hormone (LH) levels declined from 281 + 19 ng/ml to 29 + 3 ng/ml within one day | |||
| 2454805 | 1988 | [125I]IGF-I | 70 | Free | Free | Linear | L | None | Human Recombinant peptide | Stmulates glycogen synthesis | Blood collected 10 minutes to 6 hours after peptide injection | 1 µCi peptide injected to rhesus monkey | 100 | Proteases from Rat serum | Radioimmunoassay | Rat Serum | in vivo | None | None | Stimulates glycogen synthesis by the incorporation of [14C]glucose into glycogen in rat diaphragm | |||
| 2454805 | 1988 | [125I]B-chain mutant IGF-1 | 71 | Free | Free | Linear | L | None | Human Recombinant peptide | Stmulates glycogen synthesis | Blood collected 10 minutes to 6 hours after peptide injection | 2 µCi peptide injected to rhesus monkey | 27.5 | Proteases from Rat serum | Radioimmunoassay | Rat Serum | in vivo | None | None | Stimulates glycogen synthesis by the incorporation of [14C]glucose into glycogen in rat diaphragm | |||
| 2454805 | 1988 | [125I] [Gln3,Ala4,Tyr15,Leu16]IGF-1 | 70 | Free | Free | Linear | L | None | Human Recombinant peptide | Stmulates glycogen synthesis | Blood collected 10 minutes to 6 hours after peptide injection | 3 µCi peptide injected to rhesus monkey | 26.9 | Proteases from Rat serum | Radioimmunoassay | Rat Serum | in vivo | None | None | Stimulates glycogen synthesis by the incorporation of [14C]glucose into glycogen in rat diaphragm | |||
| 2498387 | 1989 | Buserelin | 9 | Free | Ethylamide | Linear | Mix | D-Ser(tBu) at 6th position, Pglu=pyr- Glutamate | Analogue of LHRH (Luteinizing hormone-releasing hormone) | Stimulates release of LH, FSH and estradiol | Blood collected 0-6 hours after peptide injection | 500 µg/kg | 11.2 (elimination t1/2 after 10-60 min of i/v injection) | Proteases from serum of women with endometriosis | Radioimmunoassay, HPLC | (Dose i/v injected)Serum of women with endometriosis | in vivo | None | None | Serum LH, FSH, and estradiol concentrations increased acutely up to 10-fold above basal values | |||
| 2498387 | 1989 | Buserelin | 9 | Free | Ethylamide | Linear | Mix | D-Ser(tBu) at 6th position | Analogue of LHRH (Luteinizing hormone-releasing hormone) | Stimulates release of LH, FSH and estradiol | Blood collected 0-6 hours after peptide injection | 500 µg/kg | 50.4 (elimination t1/2 after 60-120 mins of i/v injection) | Proteases from serum of women with endometriosis | Radioimmunoassay, HPLC | (Dose i/v injected)Serum of women with endometriosis | in vivo | None | None | Serum LH, FSH, and estradiol concentrations increased acutely up to 10-fold above basal values | |||
| 2498387 | 1989 | Buserelin | 9 | Free | Ethylamide | Linear | Mix | D-Ser(tBu) at 6th position | Analogue of LHRH (Luteinizing hormone-releasing hormone) | Stimulates release of LH, FSH and estradiol | Blood collected 0-6 hours after peptide injection | 500 µg/kg | 82.7 (elimination t1/2 after 120-360 mins of i/v injection) | Proteases from serum of women with endometriosis | Radioimmunoassay, HPLC | (Dose i/v injected)Serum of women with endometriosis | in vivo | None | None | Serum LH, FSH, and estradiol concentrations increased acutely up to 10-fold above basal values | |||
| 2521208 | 1989 | VP (Vasopressin) | 9 | Free | Amidation | Cyclic (C1-C6) | L | None | Anti-diuretic hormone secreted by pitutiary gland | Anti-diuretic and regulates retention of water | Not mentioned | 500 µg/kg | 80 (elimination t1/2 after 6-24h of i/v injection) | Proteases from urine of women with endometriosis | Radioimmunoassay, HPLC | (Dose i/v injected)urine of women with endometriosis | in vivo | None | None | Not mentioned | |||
| 2521208 | 1989 | VP (Vasopressin) | 9 | Free | Amidation | Cyclic (C1-C6) | L | None | Anti-diuretic hormone secreted by pitutiary gland | Anti-diuretic and regulates retention of water | Not mentioned | Exogenously administered | 0.9(fast component) | Proteases from Rabbit plasma | Radioimmunoassay | Rabbit plasma | in vivo | None | None | Not mentioned | |||
| 2521208 | 1989 | VP (Vasopressin) | 9 | Free | Amidation | Cyclic (C1-C6) | L | None | Anti-diuretic hormone secreted by pitutiary gland | Anti-diuretic and regulates retention of water | Not mentioned | Exogenously administered | 5.4(lower phase) | Proteases from Rabbit plasma | Radioimmunoassay | Rabbit plasma | in vivo | None | None | Not mentioned | |||
| 2521208 | 1989 | VP (Vasopressin) | 9 | Free | Amidation | Cyclic (C1-C6) | L | None | Anti-diuretic hormone secreted by pitutiary gland | Anti-diuretic and regulates retention of water | Not mentioned | Endogenously administered | 1.3 | Proteases from Rabbit plasma | Radioimmunoassay | Rabbit plasma | in vivo | None | None | Not mentioned | |||
| 2521208 | 1989 | ANP (Atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Synthetic | Natriuretic and vasodilator | Not mentioned | Exogenously administered | 1.2 | Proteases from Rabbit plasma | Radioimmunoassay | Rabbit plasma | in vivo | None | None | Not mentioned | |||
| 2521208 | 1989 | ANP (Atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Synthetic | Natriuretic and vasodilator | Not mentioned | Endoogenously administered | 3.2 | Proteases from Rabbit plasma | Radioimmunoassay | Rabbit plasma | in vivo | None | None | Not mentioned | |||
| 2687064 | 1989 | Sandostatinor SMS 201-995 | 8 | Free | OL | Cyclic (C2-C7) | Mix | None | Analogue of somatostatin | Inhibitor of Growth hormone secretion | Blood collected 12hours after peptide injection | 50 µg | 144 ±15 | Proteases from Human plasma (type 1 diabetic patients) | Radioimmunoassay | (Dose s/c injected)Human plasma (type 1diabetic patients) | in vivo | None | None | Plasma glucagon and growth hormone levels were significantly reduced after SMS 201-995 | |||
| 2866222 | 1985 | hGRF-1(1-29) (Human growth hormone-releasing factor) | 29 | Free | Amidation | Linear | L | None | Human growth hormone-releasing factor | Stimulates growth hormone release | Blood collected 2-60 minutes after peptide injection | 10 µg/200μ1 0.9% NaCl/0.5% Human Serum albumin, | 1.9 ±0.2 (alpha half life) | Rat plasma proteases | Radioimmunoassay | (Dose i/v injected)Rat plasma | in vivo | None | None | Not reported | |||
| 2866222 | 1985 | hGRF-1(1-29) (Human growth hormone-releasing factor) | 29 | Free | Amidation | Linear | L | None | Human growth hormone-releasing factor | Stimulates growth hormone release | Blood collected 2-60 minutes after peptide injection | 10 µg/200μ1 0.9% NaCl/0.5% Human Serum albumin, | 10.4 ±0.2 (beta or elimination half life) | Rat plasma proteases | Radioimmunoassay | (Dose i/v injected)Rat plasma | in vivo | None | None | Not reported | |||
| 2868381 | 1986 | Somatostatin | 14 | Free | Free | Cyclic (C3-C14) | L | None | Growth hormone €“inhibiting hormone (GHIH) | Inhibitor of Growth hormone secretion | Blood sample collected after 10 minutes in 5 minutes interval, followed by 30 minutes thricely at 1 | 250 µg peptide infused | 1.2-3.6 | Proteases from plasma of healthy Human | Radioimmunoassay | Human plasma | in vivo | None | None | Not reported | |||
| 2868381 | 1986 | Somatostatin | 14 | Free | Free | Cyclic (C3-C14) | L | None | Growth hormone €“inhibiting hormone (GHIH) | Inhibitor of Growth hormone secretion | Blood sample collected after 10 minutes in 5 minutes interval, followed by 30 minutes thricely at 1 | 250 µg peptide infused | 1.4-4.1 | Proteases from plasma of Human patient (cirrhotic subjects) | Radioimmunoassay | Plasma of Human patient (cirrhotic subjects) | in vivo | None | None | Not reported | |||
| 3108068 | 1987 | IGF-1 (Insulin-like growth factor-I) | 70 | Free | Free | Linear | L | None | Purified from bovine colostrum | Mediates growth and development | Blood collected 12hours after peptide injection | 6 - 10 µg/Kg | <15 | Proteases from chicken plasma | Radioimmunoassay | (Dose i/v injected)Chicken plasma | in vivo | None | None | GH concentrations subsequent to TRH injection were significantly depressed45.1 and 48.2% in IGF-l-treated as compared with control chicks; and GRF-stimulated GH secretion was significantly decreased by IGF-I administration in (41.3%) | |||
| 2524034 | 1989 | [Leu5]Enkephalin | 18 | Free | Free | Linear | L | None | Somatostatin | Inhibitor of Growth hormone secretion | Not mentioned | Peptide 0.04 w/v in 154mM KCl | 33 ±7 | Proteases from rat rectal proteases | HPLC | Rat rectal lumen | in vitro | None | None | Not mentioned | |||
| 2524034 | 1989 | DE-gamma-E (Des-enkephalin-gamma-endorphin) | 18 | Free | Free | Linear | L | None | Neuroleptic peptide | Neuroregulator | Not mentioned | Peptide 0.04 w/v in 154mM KCl + 0.25% w/v Na2EDTA co-administeration | 93 ±45 | Proteases from rat rectal proteases | HPLC | Rat rectal lumen | in vitro | None | None | Not mentioned | |||
| 2524034 | 1989 | [3H-Lys9]DE-gamma-E | 18 | Free | Free | Linear | L | None | Neuroleptic peptide | Neuroregulator | Not mentioned | 6 µg or 200uCi | 1.2 ±0.6 | Proteases from rat blood | HPLC | Rat blood | in vivo | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 9.2 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum (2.5%) | in vitro | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 4 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum (5%) | in vitro | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 1.9 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum (10%) | in vitro | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 0.6 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum (20%) | in vitro | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 44.6 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum (2.5%) + converting enzyme inhibitor (MK422) with conc 10-6 M | in vitro | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 8.3 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum (5%) + converting enzyme inhibitor (MK422) with conc 10-6 M | in vitro | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 4 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum(10%) + converting enzyme inhibitor (MK422) with conc 10-6 M | in vitro | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 1.2 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum (20%) + converting enzyme inhibitor (MK422) with conc 10-6 M | in vitro | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 12.6 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum (5%) + heat inactvation | in vitro | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 8.7 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum (10%) + Heat inactivation | in vitro | None | None | Not mentioned | |||
| 2556215 | 1989 | Angiotensin I (AI) | 10 | Free | Free | Linear | L | None | Derived from angiotensin | Precusor of angiotensin- II (AII) | 37 °C | 100 - 2000 ng/ml | 9.9 | Fetal calf serum proteases | Radioimmunoassay | Primary endothelial cells + Fetal calf Serum(10%) + converting enzyme inhibitor (MK422) with conc 10-6 M + heat inactivation | in vitro | None | None | Not mentioned | |||
| 2714145 | 1989 | GLP-1(72-107) (Glucagon-like peptide-1) | 36 | Free | Amidation | Linear | L | None | Glucagon-like peptide-1 derivative | Regulates glycemic index, inhibits gastric acid secretion | Not mentioned | 14.4ng/kg peptide infused from 45 min as priming dose, followed by 100 - 400 ng/kg/h dose for 45 m | 17.2 ±2 | Proteases from Human plasma | Radioimmunoassay | Human plasma | in vivo | None | None | 200pmol/L and 600pmol/L cause 16% and 23% Inhibition of pentagastrin-stimulated acid secretion respectively | |||
| 2714145 | 1989 | Truncated GLP-1(78-107) | 31 | Free | Amidation | Linear | L | None | Glucagon-like peptide-1 derivative | Regulates glycemic index, inhibits gastric acid secretion | Not mentioned | 4.8 -14.4ng/kg peptide infused from 45 min as priming dose, followed by 12.5 - 50 ng/kg/h dose for | 11.4 ±2.1 | Proteases from Human plasma | Radioimmunoassay | Human plasma | in vivo | None | None | 200pmol/L of peptide causes 36% Inhibition of pentagastrin-stimulated acid secretion respectively | |||
| 2945560 | 1986 | hANP (Human Atrial Natriuretic Peptide) | 28 | Free | Amidation | Cyclic (C7-C23) | L | None | Hormone secreted by heart muscle cells | Natriuretic and vasodilator | Not mentioned | 98.3 ± 44.6pg/ml | 5.65 | Proteases from Human plasma | Radioimmunoassay | Human plasma(bolus injection) | in vivo | None | None | Not reported | |||
| 2991517 | 1985 | Compound 16 (Ketomethylene pentapeptide analogue) | 4 | Cbc=Cyclobutanecarboxylic acid | Free | Linear | L | Proline ring is tritiated | Pentapeptide analogue of the ketomethylene-containing angiotensin converting enzyme (ACE) inhibitor | Angiotensin converting enzyme (ACE) inhibitor and anti-hypertensive | Not mentioned | 2mg | 24.4 | Proteases from rat blood | Liquid scintillation spectrometer | (Dose i/v injected) Rat blood | in vivo | None | None | Potent ACE-inhibitor with I50 =7.0nM | |||
| 2991517 | 1985 | Compound 1 (Ketomethylene pentapeptide analogue) | 1 | 5(S)-benzamido-4-oxo-6-phenylhexanoyl | Free | Linear | L | Proline ring is tritiated | Pentapeptide analogue of the ketomethylene-containing angiotensin converting enzyme (ACE) inhibitor | Angiotensin converting enzyme (ACE) inhibitor and anti-hypertensive | Not mentioned | 2mg | 11.6 | Proteases from rat blood | Liquid scintillation spectrometer | (Dose i/v injected) Rat blood | in vivo | None | None | Potent ACE-inhibitor with I50 =70nM | |||
| 2624887 | 1989 | CC-2 (Corpora cardiaca) | 8 | Free | Amidation | Linear | L | pyr-Glu= Pyro-Glutamic acid | Hypertrehalosaemic hormone in cockroaches | Activate fat body glycogen phosphorylase and increase haemolymph trehalose | 2 hours | 1-2pmol | 13.2 | Proteases from Haemolymph of american cockroach | Not mentioned | Haemolymph of american cockroach | in vivo | None | None | Increase in carbohydrates in haemolymph; simulates activation of glycogen phosphorylase and induction of trehalose synthesis | |||
| 6361234 | 1983 | Amphibian bombesin | 14 | Free | Amidation | Linear | L | Pyr=Pyro-glutamine | Skin of the frog Bombina bombina | Insulinotropic agent | Not reported | 5 pmol/kg . min for 30 min and a volume of 1 ml/min. | 3 | Calf blood proteases | Radioimmunoassay | Arterial blood sample of pedigree jersey calves | in vivo | 18185064 | None | Not mentioned | |||
| 6361234 | 1983 | Porcine gastrin releasing peptide | 27 | Free | Amidation | Linear | L | None | Gastrin releasing peptide | Stimulates the release of Gastrin | Not reported | 5 pmol/kg . min for 30 min and a volume of 1 ml/min. | 3 | Calf blood proteases | Radioimmunoassay | Arterial blood sample of pedigree jersey calves | in vivo | 18185064 | None | Not mentioned | |||
| 2939312 | 1986 | α-hANP (Alpha human atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Human atrial extracts | Natriuretic and hypotensive actions | Venous samples were drawn at 1 mln intervals for 10 mlns after injectlon and then at 15 and 30 mlns. | 100 µg | 2.5 | Human blood proteases | Radioimmunoassay | Intravenous bolus injection of 100μg alpha human atrial natriuretic factor in human | in vivo | None | None | Not mentioned | |||
| 1213660 | 1975 | Procine Proinsulin | 84 | Free | Free | Cyclic (C7-C70,C19-C83,C69-C74) | L | None | Proinsulin | Not mentioned | Not reported | 5-8.6 µg/kg were injected. | 8.2 ±0.3 | Porcine blood proteases | Radioimmunoassay | Porcine blood | in vivo | http://www.drugbank.ca/drugs/DB00186 | None | Not reported | |||
| 1213660 | 1975 | Procine C-Peptide | 34 | Free | Free | Linear | L | None | Proinsulin | Not mentioned | Not reported | 5-8.6 µg/kg were injected. | 9.9 ±0.5 | Porcine blood proteases | Radioimmunoassay | Porcine blood | in vivo | http://www.drugbank.ca/drugs/DB00187 | None | Not reported |